http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2671979-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81eb74d06ec4f63bf97e5a59263b66fc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-08 |
| filingDate | 2014-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78d2507184f664771b8b05084784da89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1f779046bc8d8b5c442b5d485036523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b9408228c4a8a0d4085e45bc8378058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29cd0b0d9463e9cf69399b540289839e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc02a77d88d1e7a8efd9ad5d164b3afa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_212fbf4fb2cdc4e4c9e956989f4c7f3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b43031bcf0bf708bf042a02b33f529f5 |
| publicationDate | 2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2671979-C2 |
| titleOfInvention | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 |
| abstract | FIELD: chemistry.SUBSTANCE: invention relates to a compound of the formula I in which Ais selected from N or CR, Ais selected from N or CRprovided that only one of Aor Acan be N; Rand Reach is independently selected from hydrogen, fluorine, chlorine; Ris selected from fluorine, chlorine, bromine, iodine, CF, cyano, (1-4C)alkyl, or a group of the formula: WXYZ, wherein W is (1-3C)alkylene; X is O-; Y is absent; Z is hydrogen; Q is selected from the group of formula II, wherein Aand Aeach is independently selected from N or CR, where each present Ris independently selected from hydrogen, halogen, (1-3C)alkyl or (1-3C)alkoxy; Ais N or CR; Ris selected from halogen, hydroxy or group W-X-Y-X-Z, where Wis absent; Xis absent or is N(R) -, where Ris hydrogen; Yis absent or represents a linking group of the formula - [CRR]-, in which q is an integer selected from 1, 2, 3 or 4, and Rand Reach is independently selected from hydrogen or (1-2C)alkyl; Xis absent or is O-, -N(R)-, where Ris hydrogen; and Zis (1-6C)alkyl, phenyl, 5- or 6-membered heteroaryl or 4-7 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from nitrogen or sulfur; and where Zoptionally further substituted with one or more substituent groups independently selected from halogen and (1-4C)alkyl, pyrrolidinyl, morpholinyl; and wherein any alkyl or heterocyclyl group present in the substituent group on Z, optionally further substituted with NRRor (1-2C)alkyl; where Rand Ris selected from (1-2C)alkyl; provided that Ris only hydrogen, halogen or t-butyl when at least one of Aand Ais N or CR, in which Ris a substituent as defined above, but not hydrogen; or Q is a group of formula III, wherein Ais selected from N or CR, where Ris selected from hydrogen; ring A is: a condensed phenyl ring; a fused 5- or 6-membered carbocyclic ring; a fused 5- or 6-membered heteroaryl ring, comprising one or two heteroatoms independently selected from N, S or O; or a fused 5-, 6- or 7-membered heterocyclic ring containing one or two heteroatoms independently selected from N, S or O; Ais selected from N, O, S, CR, C(R), NR, where Ris selected from hydrogen and Ris hydrogen, Oor (1-6C)alkyl; Ais selected from N, CR, S, S(O)or C(R); m is 0, 1 or 2; Rand Reach independently is halogen, cyano, oxo or W-X-Y-X-Z, where Wis absent or represents a linking group of the formula -[CRR]-, in which r is an integer selected from 1, 2, 3 or 4, and Rand Reach is independently selected from hydrogen or (1-2C)alkyl; Xis absent, is -O-, -N(R)- or -N(R)-C(O)O, where Ris selected from hydrogen or methyl; Yis absent or represents a linking group of the formula - [CRR]-, in which s is an integer selected from 1, 2, 3 or 4, and Rand Reach is independently selected from hydrogen or (1-2C)alkyl; Xis absent, is -O-, -C(O)O-, -N (R) - or -N (R) -C(O)O-, where Ris selected from hydrogen or methyl; and Zis hydrogen, (1-6C)alkyl, (2-6C)alkenyl, 4-7 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur; and where Zis optionally further substituted with one or more substituent groups independently selected from halogen, (1-4C)-alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, provided that when Ris hydrogen (that is, when W, X, Yand Xthere are no Zis hydrogen), then ring A is an uncondensed dioxane ring, or a pharmaceutically acceptable salt thereof. Also, the invention relates to a pharmaceutical composition for the treatment of an HSF-1-mediated condition based on said compounds.,,.EFFECT: technical result - new compounds have been obtained that can be used in medicine in the treatment of proliferative diseases, such as cancer, autoimmune or viral diseases.25 cl, 218 ex |
| priorityDate | 2013-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1933.